AU Patent

AU2016371762A1 — Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction

Assigned to Cyclerion Therapeutics Inc · Expires 2018-06-21 · 8y expired

What this patent protects

The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a gastrointestinal sphinc…

USPTO Abstract

The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a gastrointestinal sphincter disorder. Gastrointestinal sphincter disorders include, but are not limited to, an achalasia of a sphincter of the gastrointestinal tract, a spastic sphincter of the gastrointestinal tract or sphincter spasms, or a hypertensive sphincter of the gastrointestinal tract.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016371762A1
Jurisdiction
AU
Classification
—
Expires
2018-06-21
Drug substance claim
No
Drug product claim
No
Assignee
Cyclerion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.